JP6782701B2 - 脳疾患を処置するための方法および組成物 - Google Patents

脳疾患を処置するための方法および組成物 Download PDF

Info

Publication number
JP6782701B2
JP6782701B2 JP2017534822A JP2017534822A JP6782701B2 JP 6782701 B2 JP6782701 B2 JP 6782701B2 JP 2017534822 A JP2017534822 A JP 2017534822A JP 2017534822 A JP2017534822 A JP 2017534822A JP 6782701 B2 JP6782701 B2 JP 6782701B2
Authority
JP
Japan
Prior art keywords
aav
mice
mtorc1
rhes
striatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017534822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502112A5 (enExample
JP2018502112A (ja
Inventor
ビバリー エル． デイビッドソン，
ビバリー エル． デイビッドソン，
ジョン エイチ． リー，
ジョン エイチ． リー，
Original Assignee
ユニバーシティー オブ アイオワ リサーチ ファウンデーション
ユニバーシティー オブ アイオワ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ アイオワ リサーチ ファウンデーション, ユニバーシティー オブ アイオワ リサーチ ファウンデーション filed Critical ユニバーシティー オブ アイオワ リサーチ ファウンデーション
Publication of JP2018502112A publication Critical patent/JP2018502112A/ja
Publication of JP2018502112A5 publication Critical patent/JP2018502112A5/ja
Application granted granted Critical
Publication of JP6782701B2 publication Critical patent/JP6782701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017534822A 2014-12-30 2015-12-30 脳疾患を処置するための方法および組成物 Active JP6782701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098085P 2014-12-30 2014-12-30
US62/098,085 2014-12-30
PCT/US2015/068034 WO2016109649A1 (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Publications (3)

Publication Number Publication Date
JP2018502112A JP2018502112A (ja) 2018-01-25
JP2018502112A5 JP2018502112A5 (enExample) 2019-02-07
JP6782701B2 true JP6782701B2 (ja) 2020-11-11

Family

ID=56285031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017534822A Active JP6782701B2 (ja) 2014-12-30 2015-12-30 脳疾患を処置するための方法および組成物

Country Status (12)

Country Link
US (1) US11612641B2 (enExample)
EP (1) EP3240577B1 (enExample)
JP (1) JP6782701B2 (enExample)
KR (1) KR102618947B1 (enExample)
CN (1) CN107405414A (enExample)
AU (1) AU2015374043B2 (enExample)
BR (1) BR112017013674A2 (enExample)
CA (1) CA2971687C (enExample)
ES (1) ES2962439T3 (enExample)
SG (1) SG11201704829QA (enExample)
WO (1) WO2016109649A1 (enExample)
ZA (1) ZA201704327B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
KR102584655B1 (ko) 2014-11-14 2023-10-06 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
EP3240577B1 (en) 2014-12-30 2023-07-05 University of Iowa Research Foundation Therapeutic agent that activates mtorc1 function for use in treating huntington's disease
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
AU2017268382B2 (en) 2016-05-18 2023-09-28 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
CL2016003282A1 (es) * 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
WO2018132791A1 (en) * 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050009112A1 (en) 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
KR20080018874A (ko) 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
KR101286870B1 (ko) * 2009-11-30 2013-07-16 (주)아모레퍼시픽 황기 추출물을 포함하는 대사 촉진 조성물
WO2013061305A1 (en) * 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
US9511036B2 (en) * 2011-11-01 2016-12-06 Children's Medical Center Corporation Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
HK1201828A1 (en) * 2011-11-08 2015-09-11 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
US9095521B2 (en) * 2012-02-02 2015-08-04 Washington University Methods for improving muscle strength
KR101626526B1 (ko) 2014-10-30 2016-06-02 경북대학교 산학협력단 ｈＲｈｅｂ를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물
EP3240577B1 (en) 2014-12-30 2023-07-05 University of Iowa Research Foundation Therapeutic agent that activates mtorc1 function for use in treating huntington's disease

Also Published As

Publication number Publication date
HK1245127A1 (en) 2018-08-24
KR20170098931A (ko) 2017-08-30
AU2015374043A1 (en) 2017-07-13
EP3240577A1 (en) 2017-11-08
ES2962439T3 (es) 2024-03-19
WO2016109649A1 (en) 2016-07-07
CA2971687C (en) 2024-05-28
US11612641B2 (en) 2023-03-28
KR102618947B1 (ko) 2023-12-27
AU2015374043B2 (en) 2021-05-13
CN107405414A (zh) 2017-11-28
CA2971687A1 (en) 2016-07-07
BR112017013674A2 (pt) 2018-02-06
SG11201704829QA (en) 2017-07-28
ZA201704327B (en) 2025-02-26
EP3240577A4 (en) 2018-07-25
JP2018502112A (ja) 2018-01-25
EP3240577B1 (en) 2023-07-05
NZ733014A (en) 2024-05-31
US20180000907A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
JP6782701B2 (ja) 脳疾患を処置するための方法および組成物
US20240226203A9 (en) Compositions and methods of treating huntington's disease
US20220333131A1 (en) Modulatory polynucleotides
US11603542B2 (en) Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US10087224B2 (en) Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
CN108347932A (zh) 用于治疗遗传性眼病的方法和组合物
US20220275367A1 (en) Compositions and methods for treating huntington's disease
EP2187898B1 (en) Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease
CN112955169A (zh) 用于肌萎缩性侧索硬化疗法中的胆固醇24-水解酶的表达载体
JP2020519251A (ja) 結節性硬化症の遺伝子治療
JP2020515284A (ja) ポリグルタミン反復脊髄小脳失調症の処置におけるコレステロール２４−ヒドロキシラーゼ（ｈｙｄｒｏｌａｓｅ）のための発現ベクター
JP2025535780A (ja) アルツハイマー病においてｒｅｅｌｉｎを使用する組成物および方法
CN116723868A (zh) 治疗神经系统疾病的方法
HK1245127B (en) Therapeutic agent that activates mtorc1 function for use in treating huntington's disease
WO2022174036A2 (en) Methods and materials for treating tdp-43 proteinopathies
HK40052708A (zh) 用於肌萎缩性侧索硬化疗法中的胆固醇24-羟化酶的表达载体
Wu et al. Gene Therapy for Huntington’s Disease
Rodriguez Characterization of the effects of reduced mutant huntingtin in the R6/1 model of Huntington's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201020

R150 Certificate of patent or registration of utility model

Ref document number: 6782701

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250